Xencor (XNCR) Expected to Announce Earnings on Wednesday

Xencor (NASDAQ:XNCR) is anticipated to post its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Xencor to post earnings of ($0.72) per share and revenue of $29.7290 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 6:00 PM ET.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.37. The firm had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The company’s revenue for the quarter was up 82.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.07) EPS. On average, analysts expect Xencor to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Xencor Stock Performance

Shares of NASDAQ XNCR opened at $14.25 on Wednesday. The company has a market capitalization of $1.02 billion, a P/E ratio of -5.94 and a beta of 0.96. Xencor has a 52-week low of $6.92 and a 52-week high of $27.24. The company’s 50 day moving average price is $10.71 and its 200-day moving average price is $9.43.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on XNCR. Bank of America downgraded shares of Xencor from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Tuesday, October 14th. Cantor Fitzgerald upgraded shares of Xencor to a “strong-buy” rating in a research report on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and set a $26.00 target price on shares of Xencor in a research report on Tuesday, September 2nd. Finally, Wells Fargo & Company dropped their target price on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating on the stock in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $24.56.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rafferty Asset Management LLC raised its holdings in Xencor by 4.4% during the second quarter. Rafferty Asset Management LLC now owns 90,599 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 3,858 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in Xencor by 3.3% during the second quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company’s stock valued at $550,000 after buying an additional 2,256 shares during the period. Man Group plc bought a new position in Xencor during the second quarter valued at about $485,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Xencor by 9.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after buying an additional 3,692 shares during the period. Finally, AQR Capital Management LLC purchased a new stake in Xencor during the first quarter valued at about $438,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.